ImmunoPrecise Antibodies (NASDAQ:IPA) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of ImmunoPrecise Antibodies (NASDAQ:IPA) in a research note released on Tuesday, Benzinga reports. The brokerage currently has a $9.00 price target on the stock. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.30) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.16) EPS, FY2027 earnings at ($0.01) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.32 EPS.

Separately, Benchmark cut their price target on shares of ImmunoPrecise Antibodies from $5.00 to $3.00 and set a speculative buy rating on the stock in a report on Wednesday, August 14th.

ImmunoPrecise Antibodies Stock Performance

Shares of NASDAQ IPA opened at $0.67 on Tuesday. The stock’s fifty day simple moving average is $0.79 and its 200 day simple moving average is $1.09. The stock has a market capitalization of $17.63 million, a price-to-earnings ratio of -1.61 and a beta of 0.10. The company has a quick ratio of 1.15, a current ratio of 1.41 and a debt-to-equity ratio of 0.36. ImmunoPrecise Antibodies has a 52-week low of $0.53 and a 52-week high of $2.60.

ImmunoPrecise Antibodies (NASDAQ:IPA) last issued its quarterly earnings results on Monday, July 29th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.42). The company had revenue of $4.76 million during the quarter, compared to analysts’ expectations of $4.92 million. ImmunoPrecise Antibodies had a negative return on equity of 57.05% and a negative net margin of 110.66%. As a group, sell-side analysts forecast that ImmunoPrecise Antibodies will post -0.25 earnings per share for the current fiscal year.

Institutional Trading of ImmunoPrecise Antibodies

A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. Renaissance Technologies LLC boosted its stake in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 70.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 63,910 shares of the company’s stock after purchasing an additional 26,310 shares during the period. Renaissance Technologies LLC owned about 0.24% of ImmunoPrecise Antibodies worth $65,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.70% of the company’s stock.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.